For specific tumour types, the U.S. Food and Drug Administration (FDA) has approved poly (adenosine diphosphate [ADP]—ribose) polymerase (PARP) inhibitors (PARPis) for patients found to have PVs or LPVs in both germline and somatic genes involved in HRR with BRCA1/2 being one of the more common genes detected. The gene discussed is BRCA1; the disease is neoplasm.